COMP <GO>
IDXX vs UNH // FREE CASH FLOW YIELD
IDEXX Laboratories Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: IDXX 8
— UNH 6
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $672.04 (+0.06%) • MKT CAP: $52.91B
fcf-yield
2.33%
LAST: $404.44 (+1.00%) • MKT CAP: $359.43B
fcf-yield
6.25%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.80% | 88.31% | -26.51 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.60% | 12.38% | +17.22 | IDXX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.1x | 15.3x | +15.83 | UNH | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.33% | 6.25% | -3.92 | UNH | /fcf-yield <GO> |
| Operating Margin | 31.60% | 5.32% | +26.28 | IDXX | /operating-margins <GO> |
| Net Profit Margin | 24.60% | 3.53% | +21.07 | IDXX | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 3.33% | +7.07 | IDXX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.99 | 3.09 | +17.90 | IDXX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | IDXX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 73.8 | 55.1 | +18.70 | IDXX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.33 | +0.56 | IDXX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.8x | 17.7x | +22.06 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $52.91B | $359.43B | -$306.52B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXX REV | UNH REV | IDXX GROSS % | UNH GROSS % | IDXX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.30B | $447.57B | 61.8% | 88.7% | $1.06B | $16.07B |
| FY 2024 | $3.90B | $400.28B | 61.0% | 88.3% | $808.1M | $20.70B |
| FY 2023 | $3.66B | $371.62B | — | 89.6% | $741.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXX // BETA 0.89
UNH // BETA 0.33